Transforming the Treatment of Tricuspid Regurgitation
The VDyne Valve simplifies minimally invasive triscuspid valve replacement, enabling more patients to be treated
VDyne is a global medical device company developing innovative solutions for patients with tricuspid regurgitation
Some say that tricuspid regurgitation is the "forgotten valve disease." What they may not know is how significantly undertreated this disease truly is. VDyne aims to change that perception by raising awareness of tricuspid valve disease and has developed a new, minimally invasive system to address this significant unmet medical need.
The VDyne Valve System is an investigational product only that is presently undertaking human (clinical) feasibility studies. The VDyne System is not approved for sale or use for the treatment of any health condition.
Tricuspid regurgitation – or TR - is a common heart condition that affects the tricuspid valve, which is located between the atrium and the ventricle on the right side of the heart. TR occurs when the valve leaflets do not close properly, thereby allowing blood to flow backward – or regurgitate - into the right atrium. TR reduces the heart’s pumping efficiency and causes poor blood flow, which is necessary to keep us healthy and alive [i].
[iii] Kolte D, Elmariah S. Current state of transcatheter tricuspid valve repair. Cardiovasc Diagn Ther. 2020 Feb;10(1):89-97. doi: 10.21037/cdt.2019.09.11. PMID: 32175231; PMCID: PMC7044094.
1,500,000 +
People Suffering From TR (US)
< 8,000
Annual Tricuspid Interventions
High Prevalence But Limited Treatments
Despite its high prevalence, TR is a largely undertreated condition and is associated with poor life expectancy [iii]
VDYNE
Transcatheter Tricuspid Valve Replacement System
